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A growing body of evidence indicates that
inhalation of particles in the air, especially
particles from combustion-related sources,
has potential health effects for susceptible
people. A strong and consistent association
has been observed between adjusted mortal-
ity rates and ambient particle concentrations,
with an increase in the concentration of par-
ticulate matter with a mass median aerody-
namic diameter less than 10 µm (PM10) of
50 µg/m3 associated with a 3–8% increase in
relative risk of death (1). The strongest asso-
ciations are seen for respiratory and cardio-
vascular deaths, particularly among the
elderly. Associations with mortality have
been observed at mean PM10 concentrations
well below the current National Ambient Air
Quality Standard (NAAQS) for PM10 of 150
µg/m3 as a 24-hr average (1,2). Because of
concern about the potential public health
implications of these findings, the U.S.
Environmental Protection Agency (U.S.
EPA) promulgated a new standard for partic-
ulate matter with a mass median aero-
dynamic diameter of 2.5 µm (PM2.5).
Determining the biologic mechanisms
involved has been identiﬁed as a high-prior-
ity research need by the U.S. EPA and the
National Academy of Sciences (3,4).
The observed links between ambient
particle concentrations and deaths from car-
diovascular disease appear particularly puz-
zling (5). The overall mortality risk associated
with an increase in PM10 levels of 10 µg/m3
has been estimated at about 1% (2). The
highest risk is among patients with chronic
obstructive pulmonary disease (COPD)—
about 3.4%. The relative risk of cardiovascular
mortality is lower (1.4%), but because cardio-
vascular deaths outnumber COPD deaths by
a wide margin, pollution-related cardio-
vascular deaths actually outnumber COPD
deaths. The risk for cardiovascular events does
not appear to be explained by hypoxemia (6).
Recent studies in healthy and compro-
mised animals from the laboratories of the
U.S. EPA (7) and from Harvard University
(8) have suggested that inhalation of particu-
late pollutants may induce changes in cardiac
rhythm or repolarization. Panel studies have
shown that particle exposure is associated
with increases in heart rate among the elderly
(6) and decreases in heart rate variability in
active Boston residents (9).
Seaton et al. (10) have proposed that
pollutant exposure induces a transient
increase in blood coagulability as part of the
acute-phase response associated with inﬂam-
mation. This hypothesis is supported by the
recent finding that plasma viscosity is
increased on high-pollution days relative to
low-pollution days in men and women 25–64
years of age (11). Blood markers of the acute-
phase response, including C-reactive protein
(CRP), ﬁbrinogen, and interleukin (IL)-6 are
associated with cardiovascular events and
adverse outcomes (12,13). The combined
effect of these processes, i.e., effects on
myocardial function, increased blood viscos-
ity, and increased blood coagulability, could
precipitate adverse cardiac events in individu-
als with critical coronary lesions.
What are the speciﬁc particle characteristics
contributing to cardiovascular effects?
Hypotheses proposed to explain which parti-
cles are responsible have focused on issues
related to particle acidity (14), particle content
of transition metals (15), bioaerosols (16), and
ultrafine particles (UFPs; those smaller than
100 nm) (10,17). Ambient UFPs may be
important with regard to respiratory health
effects for several reasons: a) UFPs are biologi-
cally more reactive than larger-sized particles
and elicit effects at low concentrations. b)
UFPs at the same mass concentration in the
air have a much higher number concentration
and surface area than larger particles. To
achieve a low airborne concentration of 10
µg/m3, 2.4 × 106 20 nm particles/cm3 are
needed; in contrast, only one 2.5 µm particle/
cm3 is needed to reach the same concentration
(17). c) Inhaled singlet UFPs have very high
deposition efﬁciency in the pulmonary region
(e.g., 20-nm particles have up to 50% deposi-
tion efficiency (18). d) UFPs have a high
propensity to penetrate the epithelium and
reach interstitial sites (19). This raises the
intriguing possibility that UFPs could enter
the systemic circulation and induce direct
effects on myocardium or coronary vascula-
ture, although there is no direct evidence to
support this possibility.
Our proposed pathophysiology for
pollutant-related cardiovascular events is
shown in Figure 1, and involves the following
sequence of events:
a) Injury to epithelial cells by reactive
oxygen species, accompanied by activation of
nuclear regulatory factors, leading to elabora-
tion of proinﬂammatory cytokines, including
IL-8 and IL-6. 
b) Activation of vascular endothelium and
circulating polymorphonuclear leukocytes,
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eosinophils, lymphocytes, and monocytes.
Emigration of inﬂammatory cells from blood
to tissue sites involves upregulation of adhe-
sion molecules on vascular endothelium
[E-selectin, P-selectin, intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion
molecule-1] and on circulating leukocytes
(L-selectin, lymphocyte function associated
antigen-1, Mac-1, very late activation
antigen-4, ICAM-1) (20). The events in the
process of leukocyte–endothelial binding
include increased expression followed by shed-
ding of adhesion molecules as cells “tether and
roll,” cell activation, stable adhesion, and
transmigration through the epithelium (21).
Endothelial activation may contribute to the
increase in exhaled nitric oxide (NO) concen-
trations seen with airway inﬂammation. 
c) Increased release of IL-6 and tissue
factor by activated blood mononuclear cells.
IL-6 initiates hepatic synthesis of acute-phase
proteins, including CRP, serum amyloid A
(SAA), ﬁbrinogen, and plasminogen activator
inhibitor-1. Monocyte tissue factor and
endothelial cell activation initiate the coagula-
tion cascade, as reflected by the presence of
ﬁbrinopeptide A (FPA) and prothrombin1+2. 
Each step in this pathogenic sequence can
be assessed in human clinical studies, using
minimally invasive markers from blood,
exhaled air, induced sputum, and the contin-
uously recorded electrocardiogram. 
Clinical Studies of Exposure 
to UFPs
A strategy for human clinical studies of UFPs
must assure subject safety, employ particle
concentrations and composition relevant to
ambient exposures, incorporate control expo-
sures to clean, ﬁltered air, and include deter-
minations of particle retention for purposes
of dosimetry. For safety reasons, our studies
have been initiated with healthy subjects,
with the goal of studying susceptible subject
groups if there are minimal effects in healthy
subjects. Also for safety reasons, we have cho-
sen to use particles of carbon, which have
been used in inhalation studies in animals,
Figure 1. Hypothesized relationships between airway and cardiovascular responses to UFPs. iNOS, inducible nitric
oxide synthase; sE-selectin, soluble E-selectin; sL-selectin, soluble L-selectin; VNO, airway production of nitric oxide;
vWF, von-Willebrand factor.
Figure 2. Design of a facility for human clinical studies of UFP exposure. TEOM, tapered element oscillating microbalance.
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with no significant respiratory effects. These
particles do not contain trace metals or endo-
toxin. For studies of UFP exposure, particles
must be generated in real time so they remain
in singlet form. Particle collection and resus-
pension results in agglomeration, with changes
in particle size and surface area that inﬂuence
deposition, and possible health effects.
We have developed a mouthpiece
exposure system for human clinical studies
of the health effects of UFPs. The system is
designed to permit the quantitative determi-
nation of exposure levels, respiratory intakes,
and depositions of aerosols of UFPs inhaled
by human subjects. UFPs are generated in
real time using a Palas generator (Karlsruhe,
Germany). The carbon UFPs are generated
by spark discharge in an argon atmosphere
using pure graphite electrodes. Generated
particles are diluted in puriﬁed air and deliv-
ered to the subject via a one-way nonre-
breathing valve at a flow rate exceeding 80
L/min (Figure 2). Continuous measure-
ments of particle mass, number, and size dis-
tribution are performed on both the
inspiratory and expiratory sides of the sub-
ject. After correction for system losses, it is
then possible to calculate total respiratory
deposition, by particle number and mass, for
each particle size fraction. Continuous mea-
surements of minute ventilation (respiratory
rate × tidal volume) also allow calculation of
total inspired particle number and mass for
each exposure.
For initial studies in healthy subjects, we
have chosen an exposure mass concentration
of 10 µg/m3, corresponding to 2 × 106 parti-
cles/cm3. This particle number is only slightly
higher than that observed in outdoor envi-
ronments. McMurry (22) measured UFP
numbers exceeding 1,000,000/cm3 in
Atlanta, Georgia. We have observed peak par-
ticle numbers exceeding 1,700,000/cm3
above a construction site outside an acute
care hospital (23). 
Healthy, nonsmoking subjects 18–55
years of age are exposed at rest for 2 hr to
UFPs and to filtered air as a control, with a
10-min break off the mouthpiece after 1 hr.
Exposures are double-blinded, randomized,
and separated by at least 2 weeks. The total
respiratory tract deposition fraction is deter-
mined for six different particle size fractions
(midpoint diameters 7.5, 13.3, 23.7, 42.2,
75.0, and 133.4 nm) after correction for sys-
tem losses, and the overall particle number
and mass deposition is calculated for each
subject. Respiratory symptoms, spirometry,
blood pressure, pulse-oximetry, blood mark-
ers, and exhaled NO are assessed before and
immediately, 3.5 hr, and 21 hr after expo-
sure. Sputum induction is performed 21 hr
after exposure to assess inﬂammatory cells in
the conducting airways. Continuous 24-hr,
12-lead Holter monitoring is performed on
the day of the exposure and analyzed for
changes in heart rate variability and repolar-
ization phenomena. Blood markers focus on
parameters related to the acute-phase
response, blood coagulability, and circulat-
ing leukocyte activation, including the fol-
lowing: complete blood leukocyte counts
and differentials, IL-6, SAA, ﬁbrinogen, and
clotting factor VII. Immunofluorescence
and flow cytometry are used to measure
leukocyte expression of activation and adhe-
sion molecules, including ICAM-1 and
L-selectin on granulocytes and monocytes,
and CD25 on lymphocytes.
Preliminary findings indicate absence of
particle-associated symptoms or changes in
lung function in healthy subjects (24). The
overall deposition fraction was 0.66 ± 0.12 by
number and 0.58 ± 0.014 by mass. The aver-
age number deposition fraction varied among
subjects from 0.43 to 0.79. This relatively
high overall deposition is consistent with pre-
dictions for particles in this size range (18). 
Current studies are under way in healthy
subjects incorporating exercise. Exercise has
several effects that may enhance the effects of
particle exposure. First, exercise increases res-
piratory minute ventilation, increasing the
intake of the pollutant. Second, exercise
induces adrenergic hormonal responses and
changes in heart rate and heart rate variabil-
ity. Finally, exercise of sufficient intensity
induces a mild acute-phase response. These
exercise-related effects may be enhanced by
particle exposure. 
Discussion
The observed associations between outdoor
concentrations of ﬁne particulate matter and
health effects appear to be well established,
and the remarkable consistency of the data
suggests causality. However, the mechanisms
by which inhaled particles result in increased
morbidity and mortality have not been eluci-
dated. We have proposed that UFPs may be
important in the toxicity of the ambient ﬁne
particle fraction because of their relatively
high surface area and potential for crossing
the airway epithelial membrane.
The National Research Council
Commission On Geosciences, Environment,
and Resources has determined that data from
human clinical studies are needed to identify
the link between exposure and response in
both healthy and susceptible populations (4).
We have established a clinical facility for
human exposures to laboratory-generated
ultrafine carbon particles. Our preliminary
studies in healthy subjects exposed at rest to
ultraﬁne carbon particles at 10 µg/m3 suggest
no significant health effects. The relative
absence of effects in these studies was
expected because the least susceptible
subjects were chosen for these initial studies,
the particle concentrations were low, and the
particles were predicted to have low potential
for toxicity. 
Studies are under way with healthy
subjects exposed during intermittent exercise,
and planned studies will examine responses in
susceptible subject groups, including patients
with asthma. Future studies will use particles
of varying composition, including incorpora-
tion of trace metals, and will compare the
effects of UFPs with larger particles of similar
composition and mass. These human clinical
studies using model particles will comple-
ment ongoing studies of concentrated ambi-
ent fine particles, as well as epidemiologic,
animal exposure, and in vitro studies, in
determining the mechanisms for heath effects
related to ambient particle exposure.
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